Skip to main content
Clinical Trials/NCT05403801
NCT05403801
Completed
N/A

Harnessing Mobile Technology to Deliver Tailored, Brief Pain-CBT for Advanced Cancer Patients on Opioids for Pain

Dana-Farber Cancer Institute3 sites in 1 country10 target enrollmentJuly 1, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Active Cancer
Sponsor
Dana-Farber Cancer Institute
Enrollment
10
Locations
3
Primary Endpoint
Overall Intervention Adherence Rate
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.

Detailed Description

This research study involves the use of a smartphone app at home in addition to surveys and potentially an interview at the end of the study. The research study procedures include screening for eligibility, study interventions include surveys at the beginning of the study, after 4 weeks, and after 6 weeks and use of the smartphone app. Participants will be on this research study for up to 6 weeks. It is expected that about 15 people will take part in this research study This research study is a Feasibility Study, which is the first-time investigators are examining this mobile application meant to help participant to learn behavioral techniques to manage cancer pain. The purpose is to make sure the app is usable and helpful for patients with cancer, and to get feedback about patient experiences after using the app for four weeks.

Registry
clinicaltrials.gov
Start Date
July 1, 2022
End Date
June 27, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Desiree R. Azizoddin PsyD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • PILOT COHORT
  • Age ≥ 18 years
  • Patients diagnosed with an active cancer diagnosis, either undergoing active cancer treatment or receiving treatment for an advanced cancer or are receiving palliative care
  • Treatment managed at participating clinic (DFCI outpatient palliative care, gastrointestinal cancer center, and DFCI satellite clinic Merrimack Valley or Londonderry)
  • Chronic pain related to cancer or treatment (\> pain score of 4)
  • Has an active prescription for at least one opioid medication to treat their cancer pain (i.e. not for post-surgical pain)
  • Own a compatible smartphone (android) or is willing to use an android device provided by the study team
  • Completes baseline survey

Exclusion Criteria

  • Patients in survivorship: patients who have completed their treatment regimens, are not actively receiving treatment for an advanced cancer, or have a cancer that is in remission
  • Cognitive impairment that would interfere with study participation, as judged by treating clinician
  • Inability to speak English: the intervention has not yet been translated to Spanish
  • History of opioid use disorders
  • Enrolled in hospice
  • Currently hospitalized
  • Use of transmucosal fentanyl, given safety concerns and ongoing risk mitigation program required to prescribe these (TIRF REMS).
  • Pain primarily related to a recent surgery

Outcomes

Primary Outcomes

Overall Intervention Adherence Rate

Time Frame: 4 Weeks

\>70% of subjects complete \>4 of the 6 pain-CBT modules and patients will complete 50% of surveys by the end of 4 weeks (completion of the 4-week intervention study period)

Acceptability Rate

Time Frame: 4 weeks

Participants completed a modified version of the Acceptability E-scale, rating the app on a 5-point Likert scale (1-5), across 5 unique items on the following 5 domains: understandability, enjoyability, ease of use, time required to use it, and overall satisfaction.\[Tariman, 2011\] Higher scores indicated greater acceptability. Acceptability was pre-defined as \>80% across all acceptability items rated as \>4 or higher out of 5. Acceptability was evaluated by determining the mean score of all items for all participants (range of scale of score 1-5).

Secondary Outcomes

  • Number of Enrolled Participants Who Consented and Completed the Study(7 Months)
  • Study Retention(6 Months)
  • COMPREHENSIVE ENDPOINT(6 Weeks)

Study Sites (3)

Loading locations...

Similar Trials